PBM Share Price Performance
US$3.22
-60.14 (-94.92%)
Price US$3.22
Share PriceUS$3.22
Psyence Biomedical Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
PBM Community Narratives
There are no narratives available yet.
Recent PBM News & Updates
Psyence Biomedical Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 1.73
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Psyence Biomedical Ltd. Competitors
Snowflake Analysis
About PBM
- Founded
- n/a
- Employees
- 12
- CEO
- WebsiteView website
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Canadian Market Performance
- 7 Days: 1.3%
- 3 Months: 10.9%
- 1 Year: 22.4%
- Year to Date: 20.2%
Over the last 7 days, the market has risen 1.3%, driven by gains in every sector, especially the Materials sector. As for the past 12 months, the market is up 22%. Earnings are forecast to grow by 11% annually. Market details ›